Výsledky vyhledávání

Supplemental Figure 4 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

Autor: C. Patrick Reynolds, Timothy J. Triche, Daryl C. Drummond, Jonathan B. Fitzgerald, Winford Ko, Ashly Hindle, Riza E. Cruz, Ruben I. Calderon, Michael M. Song, Connor P. Hall, Nancy Paz, Joo-Sang Lee, Monish R. Makena, Jing Wang, Min H. Kang

Supplementary Figure 4: Inverse correlation between sensitivity to DNA damaging agents and SLFN11 expression.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7b21ae371c0c68ae9097ecb6dd31713
https://doi.org/10.1158/1078-0432.22460978

Zobrazit plný text záznamu

Data from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

Purpose: To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal irinotecan (nal-IRI).Experimental Design: Mouse plasma and tissue pharmacokinetics of nal-IRI and the current clinical formula

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08cdeac6283876d09e8ace69f4c91b37
https://doi.org/10.1158/1078-0432.c.6524660

Zobrazit plný text záznamu

Supplementary Tables 1 - 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

Supplementary Table 1. Human EFT, RMS, and NB cell lines used for current study. Supplementary Table 2. Median Survival of xenograft mice bearing human pediatric cancer treated with irinotecan or nal-IRI. Supplementary Table 3. Pharmacokinetic variab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::946b428e8b4f4a82a77b0d7a2b54b605
https://doi.org/10.1158/1078-0432.22460975

Zobrazit plný text záznamu

Supplemental Figure 1 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

Supplementary Figure 1: Changes in body weight of mice treated with vehicle.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36a5b770b2d9736d25b0bbae379e077d
https://doi.org/10.1158/1078-0432.22460987

Zobrazit plný text záznamu

Supplemental Figure 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

Supplementary Figure 3: Representative pictures of macrophage infiltration in tumors.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b0ed60bab2c1e32fc412c13848445a1
https://doi.org/10.1158/1078-0432.22460981.v1

Zobrazit plný text záznamu

Supplemental Figure 2 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

Supplementary Figure 2: The effect of plasma caroxylesterase activity on the conversion of CPT-11 to SN-38 in mouse and human plasma.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e57ccc489870c00939e18960aea76b6
https://doi.org/10.1158/1078-0432.22460984.v1

Zobrazit plný text záznamu

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

Autor: C. Patrick Reynolds, Michael M. Song, Min H. Kang, Jonathan Fitzgerald, Jing Wang, Monish Ram Makena, Winford Ko, Timothy J. Triche, Daryl C. Drummond, Riza E. Cruz, Ruben I. Calderon, Ashly Hindle, Connor P. Hall, Joo-Sang Lee, Nancy Paz

Publikováno v: Clinical Cancer Research. 21:1139-1150

Purpose: To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal irinotecan (nal-IRI). Experimental Design: Mouse plasma and tissue pharmacokinetics of nal-IRI and the current clinical formul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3374ec45f29c9b16d644cd4d6c3e511e
https://doi.org/10.1158/1078-0432.ccr-14-1882

Zobrazit plný text záznamu

Abstract 3972: Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewings family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression

Autor: Ashly Hindle, Nancy Paz, C. Patrick Reynolds, Michael M. Song, Connor P. Hall, Joo-Sang Lee, Jonathan Fitzgerald, Min H. Kang, Daryl C. Drummond, Monish Ram Makena, Timothy J. Triche, Winford Ko

Publikováno v: Cancer Research. 74:3972-3972

Introduction: Pharmacokinetic properties of irinotecan limit tumor exposure to the active metabolite SN-38. MM-398, a nanoliposomal irinotecan (nal-IRI) developed to attempt to enhance delivery of irinotecan and SN-38 to tumor cells is being tested i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::506d66442f75db0a4991d125dac23067
https://doi.org/10.1158/1538-7445.am2014-3972

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání